Shiyao Innovation: Subsidiary Receives $30 Million Advance Payment from AstraZeneca

Shiyao Innovation Announcement: The company's controlling subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., received a $30 million upfront payment from AstraZeneca on August 12, 2026, with the actual amount received subject to bank fees. This upfront payment corresponds to the "Collaboration, Option, and License Agreement" signed by both parties on July 1, 2026, in which they will collaborate to develop novel extrahepatic delivery small interfering molecular nucleic acid candidate drugs.